News | July 22, 2023
Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
The companies will leverage their respective proprietary technology platforms
Lutio has the potential to offer significant cost savings when available to UK patients.
Subscribe To Our Newsletter & Stay Updated
